OKYO Pharma Ltd.

Biotechnology • Healthcare • London, United Kingdom • OKYO (NCM)

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

44 20 7495 2379 14/15 Conduit St, United Kingdom

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update - MarketBeat

MarketBeat • Dec 25

OKYO Pharma Ltd Rings the Opening Bell - Nasdaq

Nasdaq • Dec 19

OKYO Pharma Stock Rises After Company Outlines Development Pathway For Neuropathic Corneal Pain Drug - Stocktwits

Stocktwits • Sep 22

OKYO Pharma Announces Chairman and Founder Acquires Shares - Yahoo Finance

Yahoo Finance • Dec 3

B.Riley initiates coverage on OKYO Pharma stock with Buy rating - Investing.com

Investing.com • Dec 8

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has OKYO Pharma Ltd had layoffs?

No layoff events have been recorded for OKYO Pharma Ltd in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does OKYO Pharma Ltd have?

OKYO Pharma Ltd has approximately 4 employees.

What industry is OKYO Pharma Ltd in?

OKYO Pharma Ltd operates in the Biotechnology industry, within the Healthcare sector.

Is OKYO Pharma Ltd a publicly traded company?

Yes, OKYO Pharma Ltd is publicly traded under the ticker symbol OKYO on the NCM. The company has a market capitalization of approximately $0.07 billion.

Where is OKYO Pharma Ltd headquartered?

OKYO Pharma Ltd is headquartered in London, United Kingdom at 14/15 Conduit St, United Kingdom.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.